Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Major stock indexes ended mixed Thursday, with the Dow Jones Industrial Average and S&P 500 closing at record highs but the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

The Financial Times covers key stories including Lululemon CEO Calvin McDonald's departure, crypto founder Do Kwon's prison sentence, Disney's $1 billion investment in OpenAI, and the end of ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...